These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
256 related articles for article (PubMed ID: 8213103)
1. Effect of norethisterone and levonorgestrel in low-dose multiphasic oral contraceptives on serum lipids. Wiik P; Nordby J; Paulsen JE Acta Obstet Gynecol Scand; 1993 Oct; 72(7):550-5. PubMed ID: 8213103 [TBL] [Abstract][Full Text] [Related]
2. A two-year clinical study of the effects of two triphasic oral contraceptives on plasma lipids. Kakis G; Powell M; Marshall A; Woutersz TB; Steiner G Int J Fertil Menopausal Stud; 1994; 39(5):283-91. PubMed ID: 7820162 [TBL] [Abstract][Full Text] [Related]
3. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism. Godsland IF; Crook D; Simpson R; Proudler T; Felton C; Lees B; Anyaoku V; Devenport M; Wynn V N Engl J Med; 1990 Nov; 323(20):1375-81. PubMed ID: 2146499 [TBL] [Abstract][Full Text] [Related]
4. Serum lipid and lipoprotein changes induced by new oral contraceptives containing ethinylestradiol plus levonorgestrel or desogestrel. Gaspard UJ; Buret J; Gillain D; Romus MA; Lambotte R Contraception; 1985 Apr; 31(4):395-408. PubMed ID: 3159546 [TBL] [Abstract][Full Text] [Related]
5. Effect of two oral contraceptives containing ethinyl estradiol and gestodene or norgestimate on different lipid and lipoprotein parameters. Wiegratz I; Jung-Hoffmann C; Gross W; Kuhl H Contraception; 1998 Aug; 58(2):83-91. PubMed ID: 9773262 [TBL] [Abstract][Full Text] [Related]
6. Lipid and biochemical changes after low-dose oral contraception. Loke DF; Ng CS; Holck S; Hall PE; Ratnam SS Contraception; 1992 Sep; 46(3):227-41. PubMed ID: 1451519 [TBL] [Abstract][Full Text] [Related]
7. Effects of three low-dose oral contraceptive formulations on lipid metabolism. Bertolini S; Elicio N; Cordera R; Gapitanio GL; Montagna G; Croce S; Saturnino M; Balestreri R; De Cecco L Acta Obstet Gynecol Scand; 1987; 66(4):327-32. PubMed ID: 2962417 [TBL] [Abstract][Full Text] [Related]
8. Relationships between blood pressure, oral contraceptive use and metabolic risk markers for cardiovascular disease. Godsland IF; Crook D; Devenport M; Wynn V Contraception; 1995 Sep; 52(3):143-9. PubMed ID: 7587185 [TBL] [Abstract][Full Text] [Related]
9. A comparative study of the effects of a monophasic and a triphasic oral contraceptive containing ethinyl estradiol and levonorgestrel on lipid and lipoprotein metabolism. Loke DF; Ng CS; Samsioe G; Holck S; Ratnam SS Contraception; 1990 Nov; 42(5):535-54. PubMed ID: 2125546 [TBL] [Abstract][Full Text] [Related]
10. Comparison of metabolic and clinical effects of four oral contraceptive formulations and a contraceptive vaginal ring. Roy S; Mishell DR; Gray G; Dozono-Takano R; Brenner PF; Eide I; de Quattro V; Shaw ST Am J Obstet Gynecol; 1980 Apr; 136(7):920-31. PubMed ID: 6767404 [TBL] [Abstract][Full Text] [Related]
11. A randomized comparative open study of the effects of two oral contraceptives, Triphasil and Ortho 7/7/7, on lipid metabolism. Kakis G; Powell M; Marshall A; Steiner G Contraception; 1993 Feb; 47(2):131-48. PubMed ID: 8449014 [TBL] [Abstract][Full Text] [Related]
12. Oral contraceptive tablets containing 20 and 30 micrograms of ethinyl estradiol with 150 micrograms desogestrel. Their influence on lipids, lipoproteins, sex hormone binding globulin and testosterone. Akerlund M; Almström E; Högstedt S; Nabrink M Acta Obstet Gynecol Scand; 1994 Feb; 73(2):136-43. PubMed ID: 8116352 [TBL] [Abstract][Full Text] [Related]